UNITED STATES
                       SECURITIES AND EXCHANGE COMMISSION
                              WASHINGTON, DC 20549

                                    FORM 8-K

                                 CURRENT REPORT
     Pursuant to Section 13 or 15(d) of The Securities Exchange Act of 1934

       Date or Report (Date of earliest event reported): December 1, 2005

                         MEDICAL MEDIA TELEVISION, INC.
             ------------------------------------------------------
             (Exact name of registrant as specified in its charter)

         Florida                         333-105840              59-3645932
------------------------------          -----------              ----------
(State or other jurisdiction of   (Commission File Number)      (IRS Employer
         incorporation)                                      Identification No.)

8406 Benjamin Road, Suite C, Tampa, Florida                        33634
-------------------------------------------                        -----
(Address of principal executive offices)                         (Zip Code)

       Registrant's telephone number, including area code: (813) 888-7330

                                       N/A
                         (Former Name or former address,
                         if changed since last report.)

Check the appropriate box below if the Form 8-K filing is intended to
simultaneously satisfy the filing obligation of the registrant under any of the
following provisions (see General Instruction A.2. below):

|_|   Written communications pursuant to Rule 425 under the Securities Act (17
      CFR 230.425)

|_|   Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR
      240.14a-12)

|_|   Pre-commencement communications pursuant to Rule 14d-2(b) under the
      Exchange Act (17 CFR 240.14d-2(b))

|_|   Pre-commencement communications pursuant to Rule 13e-4(c) under the
      Exchange Act (17CFR 240.13e-4(c))

<PAGE>

Section 2 - Financial Information

ITEM 2.03 Creation of a Direct Financial Obligation

On November 30, 2005,  Medical Media  Television,  Inc. (the  "Company")  and an
Investor  entered  into a  Confidential  Term Sheet and Letter of Intent  ("Term
Sheet")  pursuant to which the  Investor  would loan the Company an aggregate of
$1,000,000.  The Term Sheet  provides  that the Company will issue a Convertible
Promissory Note having an original aggregate face value of $1,000,000  ("Note"),
and Common Stock Purchase Warrants ("Warrants").

Pursuant to the Term Sheet,  the Company  issued a Convertible  Promissory  Note
dated November 30, 2005 for the principal amount of $1,000,000 with a term of 12
months.  Interest will be compounded  semi-annually and be payable at the end of
each quarter in either (i) shares of Series C Zero Coupon Preferred Stock of the
Company  valued a $1.00 per share,  or (ii) cash, at the option of the Investor.
The first  interest  payment will be due  December  31, 2005.  The Series C Zero
Coupon  Preferred stock shall be convertible into shares of the Company's Common
Stock on the Maturity  Date at a 10% discount to the  then-current  market price
based  on the  average  closing  price  for the  twenty  (20)  days  immediately
preceding  the  conversion.  The Investor  will loan the Company the  $1,000,000
based on the following loan schedule:

         Loan Schedule:   November 30, 2005   $175,000
                          December 4, 2005    $250,000
                          December 15, 2005   $250,000
                          January 15, 2006    $325,000

On the date of  maturity  of the Note,  the  Investor  will  have the  option to
convert the Note into shares of the Company's Common Stock at a Fixed Conversion
Price of $0.40 per share. With the consent of both the Company and the Investor,
the Note may be  extended  for an  additional  12 months,  with the terms of the
interest  payments  remaining the same. The Note shall not be  convertible  such
that the  Investor's  overall  Common  Stock  ownership  position in the Company
exceeds 4.99%;  provided,  however, that upon the Investor providing the Company
with  sixty-one  (61) days notice (the "Waiver  Notice") that the Investor would
like to waive this  restriction with regard to any or all shares of Common Stock
issuable upon exercise of the conversion  feature of the Note, this  restriction
will be of no  force or  effect  with  regard  to all or a  portion  of the Note
referenced in the Waiver Notice,  and provided further that this provision shall
be of no further  force or effect  during the  sixty-one  (61) days  immediately
preceding the expiration of the term of the Note.

Pursuant to the Term Sheet, the Company will issue the Investor its Common Stock
Purchase  Warrants (the "Warrants") to purchase an aggregate of 2,500,000 shares
of the Company's  Common Stock.  The Warrants will be issued on a pro rata basis
per the loan schedule, as follows:

                         November 30, 2005        437,500 warrants
                         December 4, 2005         625,000 warrants
                         December 15, 2005        625,000 warrants
                         January 15, 2005         812,500 warrants

The Warrants  have a term of five (5) years with an exercise  price of $0.75 per
share (the "Exercise  Price").  The Warrants are not  exercisable  such that the
Investor's overall Common Stock ownership position in the Company exceeds 4.99%.

                                       2
<PAGE>

The first two payments  according to the loan schedule were received on December
1, 2005 and December 5, 2005  respectively and the Company issued a Common Stock
Purchase Warrant to the Investor for 437,500 shares and 625,000 shares.

Terms specify that the Company,  at its earliest  opportunity,  and in any event
not more than 120 days  from the date of the  transaction,  register  all of the
Investor's underlying equity positions in the Company pursuant to a registration
statement filed with the SEC, and that such registration  statement will be kept
effective for a period of 3 years, subject to customary carve-outs.

Section 3 - Securities and Trading Markets

Item 3.02 Unregistered Sales of Equity Securities

On November 30, 2005,  Medical Media  Television,  Inc. (the  "Company")  and an
Investor  entered  into a  Confidential  Term Sheet and Letter of Intent  ("Term
Sheet")  pursuant to which the  Investor  would loan the Company an aggregate of
$1,000,000.  The Term Sheet  provides  that the Company will issue a Convertible
Promissory Note having an original aggregate face value of $1,000,000  ("Note"),
and Common Stock Purchase Warrants ("Warrants").

Pursuant to the Term Sheet,  the Company  issued a Convertible  Promissory  Note
dated November 30, 2005 for the principal amount of $1,000,000 with a term of 12
months.  Interest will be compounded  semi-annually and be payable at the end of
each quarter in either (i) shares of Series C Zero Coupon Preferred Stock of the
Company  valued a $1.00 per share,  or (ii) cash, at the option of the Investor.
The first  interest  payment will be December 31, 2005. The Series C Zero Coupon
Preferred stock shall be convertible  into shares of the Company's  Common Stock
on the Maturity Date at a 10% discount to the then-current market price based on
the average  closing  price for the twenty (20) days  immediately  preceding the
conversion.  The Investor will loan the Company an aggregate of $1,000,000 based
on the following loan schedule:

         Loan Schedule:   November 30, 2005      $175,000
                          December 4, 2005       $250,000
                          December 15, 2005      $250,000
                          January 15, 2006       $325,000

On the date of  maturity  of the Note,  the  Investor  will  have the  option to
convert the Note into shares of the Company's Common Stock at a Fixed Conversion
Price of $0.40 per share. With the consent of both the Company and the Investor,
the Note may be  extended  for an  additional  12 months,  with the terms of the
interest  payments  remaining the same. The Note shall not be  convertible  such
that the  Investor's  overall  Common  Stock  ownership  position in the Company
exceeds 4.99%;  provided,  however, that upon the Investor providing the Company
with  sixty-one  (61) days notice (the "Waiver  Notice") that the Investor would
like to waive this  restriction with regard to any or all shares of Common Stock
issuable upon exercise of the conversion  feature of the Note, this  restriction
will be of no  force or  effect  with  regard  to all or a  portion  of the Note
referenced in the Waiver Notice,  and provided further that this provision shall
be of no further  force or effect  during the  sixty-one  (61) days  immediately
preceding the expiration of the term of the Note.

Pursuant to the Term Sheet, the Company will issue the Investor its Common Stock
Purchase  Warrants (the "Warrants") to purchase an aggregate of 2,500,000 shares
of the Company's  Common Stock.  The Warrants will be issued on a pro rata basis
per the loan schedule, as follows:


                                       3
<PAGE>

                       November 30, 2005       437,500 warrants
                       December 4, 2005        625,000 warrants
                       December 15, 2005       625,000 warrants
                       January 15, 2005        812,500 warrants

The Warrants  have a term of five (5) years with an exercise  price of $0.75 per
share (the "Exercise  Price").  The Warrants are not  exercisable  such that the
Investor's overall Common Stock ownership position in the Company exceeds 4.99%.

The first two payments  according to the loan schedule were received on December
1, 2005 and December 5, 2005  respectively and the Company issued a Common Stock
Purchase Warrant to the Investor for 437,500 shares and 625,000 shares.

Terms specify that the Company,  at its earliest  opportunity,  and in any event
not more than 120 days  from the date of the  transaction,  register  all of the
Investor's underlying equity positions in the Company pursuant to a registration
statement filed with the SEC, and that such registration  statement will be kept
effective for a period of 3 years, subject to customary carve-outs.

In connection with the funding,  the Company paid an $80,000 cash consulting fee
and agreed to issue 300,000 Common Stock Purchase  Warrants to Allderdice Media,
Inc.  Such Common Stock  Purchase  Warrants  shall have a term of five (5) years
from the effective  date,  shall have an exercise price of $0.75 per share,  and
shall have a cashless exercise provision.

The  securities  sold  pursuant  to this filing  constitute  more than 5% of the
number of shares of outstanding of the Company's  Common Stock.  The issuance of
the Note and  Warrants  were exempt from the  registration  requirements  of the
Securities Act of 1933, as amended (the "Act"),  pursuant to Section 4(2) of the
Act for  transactions not involving a public offering and based on the fact that
the Notes and Warrants were issued to an  accredited  investor who had access to
the Company's financial and other relevant information.

Section 5 - Corporate Governance and Management

Item 5.02 Departure of Directors or Principal  Officers;  Election of Directors;
          Appointment of Principal Officers.

Change in Board of Directors

      Pursuant to the Merger  Agreement by and among  African  American  Medical
Network, Inc., AFMN, Inc., Medical Media Television,  Inc., and AAMN Acquisition
Sub, Inc., as amended, and consummated on November 16, 2005, the Company's board
of  directors,  effective  November  16, 2005 through  December  31,  2006,  was
established as:

                  Philip M. Cohen, Chairman
                  Charles V. Richardson
                  Randall Maxey, M.D.
                  Jeffrey I. Werber, DVM
                  Bernard J. Kouma
                  J. Holt Smith, Esq.


                                       4
<PAGE>

      On December 2, 2005, two additional directors,  Donald R. Mastropietro and
Michael  Marcovsky,  were elected as directors.  Also Bernard J. Kouma submitted
his  resignation  from the board of  directors  effective  December  2, 2005.  A
biographical  sketch of the new board members,  Charles V.  Richardson,  Randall
Maxey, M.D., Donald R. Mastropietro, and Michael Marcovsky, follows:

      Charles  V.  Richardson  - Mr.  Richardson  was  elected  to the  Board of
Directors of Medical Media on November 16, 2005. From April 2004 to November 16,
2005, Mr. Richardson served as Chairman of the Board, President, Chief Executive
Officer, and Treasurer of AFMN, Inc. and African American Medical Network,  Inc.
Mr.  Richardson  continues  to serve as a director of African  American  Medical
Network,  Inc. From March 2001 to April 2004, Mr.  Richardson served as Director
of Healthcare Marketing with Footsteps,  LLC, a marketing and advertising agency
specializing in culturally  relevant,  customized  communications  targeting the
multicultural  marketplace.  Footsteps, LLC is the multicultural  communications
company affiliated with Omnicom,  one of the world's largest  advertising agency
holding  companies.  From March  1996 to  February  2001,  he was  President  of
TRIAD/TRG, Inc., a marketing and advertising communications company specializing
in the African  American market providing  market  research,  public  relations,
sales  promotion,   and  strategic  planning  to  Fortune  1000  companies,  the
healthcare   industry,   and  government   agencies.   He  is  a  marketing  and
communications  expert who has specialized in the urban consumer market for more
than 25 years. His special expertise in the African American consumer market has
led to many  accomplishments,  including:  (i)  creating  award  winning,  image
enhancing,  communications  and community  outreach  campaigns that successfully
generated  bottom-line  results;  (ii)  implementing  successful  communications
programs for  healthcare  clients to educate and inform target  audiences  about
best practices,  preventative care, and treatments for asthma,  AIDS, stress and
high  blood  pressure,  and  diabetes;  and (iii)  corporate  involvements  with
assignments in managerial  market research  positions at Squibb,  Beechnut,  and
Lever Brothers.  In 1972, Mr.  Richardson  founded the first marketing  research
company  in the United  States to focus  exclusively  on the Black and  Hispanic
consumer  markets.  Mr.  Richardson has been a regular  lecturer on relationship
marketing  and  has  taught  seminars  on  marketing  and  promoting  healthcare
awareness and  preventative  care to urban consumers for the New York Department
of Social  Services.  He earned a B.A.  in Business  Administration  at Syracuse
University and has served on the University's  Public Relations Advisory Council
for more than 8 years.

      Randall Maxey,  M.D. -- Dr. Maxey was elected to the board of directors of
Medical Media on November 16, 2005. Previously,  Dr. Maxey served as director of
AFMN, Inc. He currently  serves as director of African American Medical Network,
Inc. and is the  Chairman of its Medical  Advisory  Board.  In the course of his
scientific and academic career, Dr. Maxey has made outstanding  contributions to
research  regarding the prevention and treatment of renal failure  especially in
cases complicated by cardiovascular  disease.  Over the years, his work has been
recognized  with  awards  from  peers,  colleagues,   and  medical  professional
organizations,  i.e.  the  National  Medical  Association  and the Golden  State
Medical Association.  In 1998, one of Dr. Maxey's most significant  achievements
was  recognized by Guam Memorial  Hospital  where he provided new  approaches to
preventing renal failure to diabetes  mellitus and hypertension in South Pacific
Islanders.

      Dr. Maxey earned his bachelor's  degree in pharmacy from the University of
Cincinnati in 1966, and concurrently,  his Ph.D. in cardiovascular  pharmacology
from Howard University  Graduate School and M.D. from Howard University  College
of Medicine (1966-1972).  Following  post-graduate training in the department of
medicine at Harlem Hospital Center,  Dr. Maxey was a postdoctoral  fellow at the
State University of New York at Downstate Medical Center in Brooklyn,  New York.
From 1973 to 1996,  Dr. Maxey served as director of nephrology at Daniel Freeman
Hospital  and Robert F. Kennedy  Medical  Center,  both  located in  California.
Currently,  Dr. Maxey is serving concurrent  positions as medical director,  and
supervising  medical director in California,  and at various  locations in Guam.
Similarly,   Dr.  Maxey  also  has  concurrent  hospital  appointments  in  both
California and Guam.


                                       5
<PAGE>

      A devoted educator and mentor, Dr. Maxey has held academic appointments at
Charles R. Drew University,  California, Downstate Medical Center, New York, and
Howard   University,   Washington,   D.C.,   where  he  directed   the  Academic
Reinforcement Program and taught the basic sciences in the College of Dentistry.

      Donald R.  Mastropietro -- Mr.  Mastropietro  was elected as a director of
Medical Media on December 2, 2005 and he currently  serves as Sr. Vice President
Finance,  Chief  Financial  Officer,  Treasurer,  and Assistant  Secretary.  Mr.
Mastropietro  started with Medical Media in August 2002. From May 1999 to August
2002, Mr.  Mastropietro  held accounting  positions with  Intelliworxx,  Inc., a
publicly  traded company  specializing in the design,  manufacture,  and sale of
hand-held  computers,  also serving as Corporate Secretary from March 2000. From
1996  until he joined  Intelliworxx,  Mr.  Mastropietro  worked  as a  financial
consultant  for several  public and  private  companies.  From 1993 to 1996,  he
served as Chief Financial Officer of EVRO Corporation, a publicly traded holding
company.  From 1972 to 1993, Mr. Mastropietro held several accounting  positions
at  Teltronics,  Inc, a publicly  traded  company  specializing  in the  design,
manufacture,  and sale of  telecommunication  equipment,  serving  the last five
years as Vice President of Finance,  Chief  Financial  Officer,  Secretary,  and
Treasurer.

      Michael  Marcovsky -- Mr.  Marcovsky  was elected as a director of Medical
Media on December 1, 2005. He  previously  served as a director of Medical Media
from April 19, 2004 through  November 16,  2005.  From 1980 to the present,  Mr.
Marcovsky  has  served as  President  and owner of Marnel  Associates,  Ltd.,  a
multi-tiered,   Los  Angeles-based   communications  firm  where  Mr.  Marcovsky
developed  strategies  for entry  into new arenas of pay  television,  cable and
pay-per-view for a list of clients that includes Citibank,  CBS, ABC, Cox Cable,
and Playboy Enterprises. From 1990 to 1994, Mr. Marcovsky served as Chairman and
CEO of The  Nostalgia  Network,  Inc. He is a pioneer in the cable and  cellular
communications  industries  and has intensive  experience  in the  entertainment
arena regarding Pay TV, Internet/E Commerce,  and Pay-Per-View.  Previously,  he
was Vice President of Program  Operations  with Warner Cable,  Vice President of
Pay-TV for Buena Vista  Distribution  (a  division of Walt Disney  Productions),
President of Golden West  Subscription  Television  and member of the  Executive
Committee of Golden West  Broadcasters.  As adjunct  professor at St. John's and
New York  Universities,  Mr. Marcovsky holds a Bachelor of Science from New York
University, and an MBA from Fordham University.

Appointment of Principal Officers

      On  December  2, 2005,  the  Company  appointed  its  principal  Executive
         Officers as:

      Philip M. Cohen, Chairman, President, Chief Executive Officer

      Donald R.  Mastropietro,  Sr.  Vice  President  Finance,  Chief  Financial
         Officer, Treasurer, and Assistant Secretary

      Charles V.  Richardson,  Sr. Vice  President  Marketing,  Chief  Marketing
         Officer

      Teresa  J.  Bray,  Vice  President  Administration/Compliance,   Corporate
         Secretary

      A biographical sketch of the new executive officer, Charles V. Richardson,
        is included above.

      On December 2, 2005, the Company ratified a five-year Employment Agreement
with Donald R.  Mastropietro  with an effective  date of November 16, 2005.  The
material terms of the Employment Agreement are as follows: (a) base compensation
of $128,400  per year,  plus  medical  insurance;  (b) salary  increases  at the
discretion  of the board of  directors  of the Company;  (c)  terminable  by the
Company at any time, for cause,  with notice and sixty days to cure any material
breach of the employment agreement; (d) terminable by the Company without cause,
with notice and payment of six months'  severance pay


                                       6
<PAGE>

based on compensation then in effect;  (e) terminable by Mr.  Mastropietro,  for
cause,  with notice and the Company's payment of six months' severance pay based
on compensation then in effect; and (f) terminable by Mr. Mastropietro,  without
cause,  with  notice.  On  December  2, 2005,  the  Company  ratified  the First
Amendment to the  Employment  Agreement  (the  "Amendment  Agreement")  with Mr.
Mastropietro  with an effective date of November 29, 2005. The principal term of
the Amendment  Agreement was that Mr.  Mastropietro's  current salary of $90,000
will remain in effect until such time as the increased salary of $128,400 as set
forth in the Employment  Agreement can be paid through cash flow from operations
of the Company.

      On December 2, 2005, the Company ratified a five-year Employment Agreement
with Teresa J. Bray with an effective  date of November  16, 2005.  The material
terms of the  Employment  Agreement  are as follows:  (a) base  compensation  of
$118,400  per  year,  plus  medical  insurance;  (b)  salary  increases  at  the
discretion  of the board of  directors  of the Company;  (c)  terminable  by the
Company at any time, for cause,  with notice and sixty days to cure any material
breach of the employment agreement; (d) terminable by the Company without cause,
with notice and payment of six months'  severance pay based on compensation then
in effect;  (e) terminable by Ms. Bray, for cause, with notice and the Company's
payment of six months' severance pay based on compensation  then in effect;  and
(f) terminable by Ms. Bray, without cause, with notice. On December 2, 2005, the
Company ratified the First Amendment to the Employment Agreement (the "Amendment
Agreement")  with Ms. Bray with an  effective  date of November  29,  2005.  The
principal term of the Amendment  Agreement was that Ms. Bray's current salary of
$80,000  will  remain  in effect  until  such  time as the  increased  salary of
$118,400 as set forth in the Employment  Agreement can be paid through cash flow
from operations of the Company.

      On December 2, 2005,  the Company  ratified an Employment  Agreement  with
Charles V.  Richardson with an effective date of November 16, 2005. The material
terms of the  Employment  Agreement  are as follows:  (a) base  compensation  of
$150,000  per  year,  plus  medical  insurance;  (b)  salary  increases  at  the
discretion  of the board of  directors  of the Company;  (c)  terminable  by the
Company at any time, for cause,  with notice and sixty days to cure any material
breach of the employment agreement; (d) terminable by the Company without cause,
with notice and payment of six months'  severance pay based on compensation then
in effect;  (e)  terminable by Mr.  Richardson,  for cause,  with notice and the
Company's  payment of six months'  severance pay based on  compensation  then in
effect;  and (f) terminable by Mr.  Richardson,  without cause, with notice. The
Employment Agreement has a termination date of March 31, 2009.

Section 9 - Financial Statements and Exhibits

Item 9.01. Financial Statements and Exhibits

      (a)   Financial Statements

            None.

      (b)   Pro Forma Financial Information

            None.

      (c)   Exhibits

            10.1  Form of Note Purchase Agreement

            10.2  Form of Convertible Promissory Note



                                       7
<PAGE>

            10.3  Form of Common Stock Purchase Warrant

            10.4  Employment   Agreement  between  the  Company  and  Donald  R.
                  Mastropietro dated November 16, 2005

            10.5  First  Amendment  to the  Employment  Agreement  of  Donald R.
                  Mastropietro dated November 29, 2005

            10.6  Employment  Agreement  between  the Company and Teresa J. Bray
                  dated November 16, 2005

            10.7  First Amendment to the Employment  Agreement of Teresa J. Bray
                  dated November 29, 2005

            10.8  Employment  Agreement  between  the  Company  and  Charles  V.
                  Richardson dated November 16, 2005

                                   SIGNATURES

      Pursuant to the  requirements of the Securities  Exchange Act of 1934, the
Registrant  has duly  caused  this  report  to be  signed  on its  behalf by the
undersigned thereunto duly authorized.

                                         MEDICAL MEDIA TELEVISION, INC.
                                                (Registrant)

Date:    December 6, 2005                By: /s/Philip M. Cohen
                                             ------------------------------
                                             Philip M. Cohen, President and
                                             Chief Executive Officer


                                       8
{"company-data": {"conformed-name": "Medical Media Television, Inc.", "cik": "0001235899", "assigned-sic": "8200", "irs-number": "593645932", "state-of-incorporation": "FL", "fiscal-year-end": "1231"}, "filing-values": {"form-type": "8-K", "act": "34", "file-number": "333-105840", "film-number": "051249570"}, "business-address": {"street1": "MEDICAL MEDIA TELEVISION, INC.", "street2": "8406 BENJAMIN ROAD, SUITE C", "city": "TAMPA", "state": "FL", "zip": "33634", "phone": "813-888-7330"}, "mail-address": {"street1": "MEDICAL MEDIA TELEVISION, INC.", "street2": "8406 BENJAMIN ROAD, SUITE C", "city": "TAMPA", "state": "FL", "zip": "33634"}, "former-company": {"former-conformed-name": "PETCARE TELEVISION NETWORK INC", "date-changed": "20030527"}}
UNITED STATES
                       SECURITIES AND EXCHANGE COMMISSION
                              WASHINGTON, DC 20549

                                    FORM 8-K

                                 CURRENT REPORT
     Pursuant to Section 13 or 15(d) of The Securities Exchange Act of 1934

       Date or Report (Date of earliest event reported): December 1, 2005

                         MEDICAL MEDIA TELEVISION, INC.
             ------------------------------------------------------
             (Exact name of registrant as specified in its charter)

         Florida                         333-105840              59-3645932
------------------------------          -----------              ----------
(State or other jurisdiction of   (Commission File Number)      (IRS Employer
         incorporation)                                      Identification No.)

8406 Benjamin Road, Suite C, Tampa, Florida                        33634
-------------------------------------------                        -----
(Address of principal executive offices)                         (Zip Code)

       Registrant's telephone number, including area code: (813) 888-7330

                                       N/A
                         (Former Name or former address,
                         if changed since last report.)

Check the appropriate box below if the Form 8-K filing is intended to
simultaneously satisfy the filing obligation of the registrant under any of the
following provisions (see General Instruction A.2. below):

|_|   Written communications pursuant to Rule 425 under the Securities Act (17
      CFR 230.425)

|_|   Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR
      240.14a-12)

|_|   Pre-commencement communications pursuant to Rule 14d-2(b) under the
      Exchange Act (17 CFR 240.14d-2(b))

|_|   Pre-commencement communications pursuant to Rule 13e-4(c) under the
      Exchange Act (17CFR 240.13e-4(c))
Section 2 - Financial Information

ITEM 2.03 Creation of a Direct Financial Obligation

On November 30, 2005,  Medical Media  Television,  Inc. (the  "Company")  and an
Investor  entered  into a  Confidential  Term Sheet and Letter of Intent  ("Term
Sheet")  pursuant to which the  Investor  would loan the Company an aggregate of
$1,000,000.  The Term Sheet  provides  that the Company will issue a Convertible
Promissory Note having an original aggregate face value of $1,000,000  ("Note"),
and Common Stock Purchase Warrants ("Warrants").

Pursuant to the Term Sheet,  the Company  issued a Convertible  Promissory  Note
dated November 30, 2005 for the principal amount of $1,000,000 with a term of 12
months.  Interest will be compounded  semi-annually and be payable at the end of
each quarter in either (i) shares of Series C Zero Coupon Preferred Stock of the
Company  valued a $1.00 per share,  or (ii) cash, at the option of the Investor.
The first  interest  payment will be due  December  31, 2005.  The Series C Zero
Coupon  Preferred stock shall be convertible into shares of the Company's Common
Stock on the Maturity  Date at a 10% discount to the  then-current  market price
based  on the  average  closing  price  for the  twenty  (20)  days  immediately
preceding  the  conversion.  The Investor  will loan the Company the  $1,000,000
based on the following loan schedule:

         Loan Schedule:   November 30, 2005   $175,000
                          December 4, 2005    $250,000
                          December 15, 2005   $250,000
                          January 15, 2006    $325,000

On the date of  maturity  of the Note,  the  Investor  will  have the  option to
convert the Note into shares of the Company's Common Stock at a Fixed Conversion
Price of $0.40 per share. With the consent of both the Company and the Investor,
the Note may be  extended  for an  additional  12 months,  with the terms of the
interest  payments  remaining the same. The Note shall not be  convertible  such
that the  Investor's  overall  Common  Stock  ownership  position in the Company
exceeds 4.99%;  provided,  however, that upon the Investor providing the Company
with  sixty-one  (61) days notice (the "Waiver  Notice") that the Investor would
like to waive this  restriction with regard to any or all shares of Common Stock
issuable upon exercise of the conversion  feature of the Note, this  restriction
will be of no  force or  effect  with  regard  to all or a  portion  of the Note
referenced in the Waiver Notice,  and provided further that this provision shall
be of no further  force or effect  during the  sixty-one  (61) days  immediately
preceding the expiration of the term of the Note.

Pursuant to the Term Sheet, the Company will issue the Investor its Common Stock
Purchase  Warrants (the "Warrants") to purchase an aggregate of 2,500,000 shares
of the Company's  Common Stock.  The Warrants will be issued on a pro rata basis
per the loan schedule, as follows:

                         November 30, 2005        437,500 warrants
                         December 4, 2005         625,000 warrants
                         December 15, 2005        625,000 warrants
                         January 15, 2005         812,500 warrants

The Warrants  have a term of five (5) years with an exercise  price of $0.75 per
share (the "Exercise  Price").  The Warrants are not  exercisable  such that the
Investor's overall Common Stock ownership position in the Company exceeds 4.99%.

                                       2
The first two payments  according to the loan schedule were received on December
1, 2005 and December 5, 2005  respectively and the Company issued a Common Stock
Purchase Warrant to the Investor for 437,500 shares and 625,000 shares.

Terms specify that the Company,  at its earliest  opportunity,  and in any event
not more than 120 days  from the date of the  transaction,  register  all of the
Investor's underlying equity positions in the Company pursuant to a registration
statement filed with the SEC, and that such registration  statement will be kept
effective for a period of 3 years, subject to customary carve-outs.

Section 3 - Securities and Trading Markets

Item 3.02 Unregistered Sales of Equity Securities

On November 30, 2005,  Medical Media  Television,  Inc. (the  "Company")  and an
Investor  entered  into a  Confidential  Term Sheet and Letter of Intent  ("Term
Sheet")  pursuant to which the  Investor  would loan the Company an aggregate of
$1,000,000.  The Term Sheet  provides  that the Company will issue a Convertible
Promissory Note having an original aggregate face value of $1,000,000  ("Note"),
and Common Stock Purchase Warrants ("Warrants").

Pursuant to the Term Sheet,  the Company  issued a Convertible  Promissory  Note
dated November 30, 2005 for the principal amount of $1,000,000 with a term of 12
months.  Interest will be compounded  semi-annually and be payable at the end of
each quarter in either (i) shares of Series C Zero Coupon Preferred Stock of the
Company  valued a $1.00 per share,  or (ii) cash, at the option of the Investor.
The first  interest  payment will be December 31, 2005. The Series C Zero Coupon
Preferred stock shall be convertible  into shares of the Company's  Common Stock
on the Maturity Date at a 10% discount to the then-current market price based on
the average  closing  price for the twenty (20) days  immediately  preceding the
conversion.  The Investor will loan the Company an aggregate of $1,000,000 based
on the following loan schedule:

         Loan Schedule:   November 30, 2005      $175,000
                          December 4, 2005       $250,000
                          December 15, 2005      $250,000
                          January 15, 2006       $325,000

On the date of  maturity  of the Note,  the  Investor  will  have the  option to
convert the Note into shares of the Company's Common Stock at a Fixed Conversion
Price of $0.40 per share. With the consent of both the Company and the Investor,
the Note may be  extended  for an  additional  12 months,  with the terms of the
interest  payments  remaining the same. The Note shall not be  convertible  such
that the  Investor's  overall  Common  Stock  ownership  position in the Company
exceeds 4.99%;  provided,  however, that upon the Investor providing the Company
with  sixty-one  (61) days notice (the "Waiver  Notice") that the Investor would
like to waive this  restriction with regard to any or all shares of Common Stock
issuable upon exercise of the conversion  feature of the Note, this  restriction
will be of no  force or  effect  with  regard  to all or a  portion  of the Note
referenced in the Waiver Notice,  and provided further that this provision shall
be of no further  force or effect  during the  sixty-one  (61) days  immediately
preceding the expiration of the term of the Note.

Pursuant to the Term Sheet, the Company will issue the Investor its Common Stock
Purchase  Warrants (the "Warrants") to purchase an aggregate of 2,500,000 shares
of the Company's  Common Stock.  The Warrants will be issued on a pro rata basis
per the loan schedule, as follows:

                                       3
November 30, 2005       437,500 warrants
                       December 4, 2005        625,000 warrants
                       December 15, 2005       625,000 warrants
                       January 15, 2005        812,500 warrants

The Warrants  have a term of five (5) years with an exercise  price of $0.75 per
share (the "Exercise  Price").  The Warrants are not  exercisable  such that the
Investor's overall Common Stock ownership position in the Company exceeds 4.99%.

The first two payments  according to the loan schedule were received on December
1, 2005 and December 5, 2005  respectively and the Company issued a Common Stock
Purchase Warrant to the Investor for 437,500 shares and 625,000 shares.

Terms specify that the Company,  at its earliest  opportunity,  and in any event
not more than 120 days  from the date of the  transaction,  register  all of the
Investor's underlying equity positions in the Company pursuant to a registration
statement filed with the SEC, and that such registration  statement will be kept
effective for a period of 3 years, subject to customary carve-outs.

In connection with the funding,  the Company paid an $80,000 cash consulting fee
and agreed to issue 300,000 Common Stock Purchase  Warrants to Allderdice Media,
Inc.  Such Common Stock  Purchase  Warrants  shall have a term of five (5) years
from the effective  date,  shall have an exercise price of $0.75 per share,  and
shall have a cashless exercise provision.

The  securities  sold  pursuant  to this filing  constitute  more than 5% of the
number of shares of outstanding of the Company's  Common Stock.  The issuance of
the Note and  Warrants  were exempt from the  registration  requirements  of the
Securities Act of 1933, as amended (the "Act"),  pursuant to Section 4(2) of the
Act for  transactions not involving a public offering and based on the fact that
the Notes and Warrants were issued to an  accredited  investor who had access to
the Company's financial and other relevant information.

Section 5 - Corporate Governance and Management

Item 5.02 Departure of Directors or Principal  Officers;  Election of Directors;
          Appointment of Principal Officers.

Change in Board of Directors

      Pursuant to the Merger  Agreement by and among  African  American  Medical
Network, Inc., AFMN, Inc., Medical Media Television,  Inc., and AAMN Acquisition
Sub, Inc., as amended, and consummated on November 16, 2005, the Company's board
of  directors,  effective  November  16, 2005 through  December  31,  2006,  was
established as:

                  Philip M. Cohen, Chairman
                  Charles V. Richardson
                  Randall Maxey, M.D.
                  Jeffrey I. Werber, DVM
                  Bernard J. Kouma
                  J. Holt Smith, Esq.

                                       4
On December 2, 2005, two additional directors,  Donald R. Mastropietro and
Michael  Marcovsky,  were elected as directors.  Also Bernard J. Kouma submitted
his  resignation  from the board of  directors  effective  December  2, 2005.  A
biographical  sketch of the new board members,  Charles V.  Richardson,  Randall
Maxey, M.D., Donald R. Mastropietro, and Michael Marcovsky, follows:

      Charles  V.  Richardson  - Mr.  Richardson  was  elected  to the  Board of
Directors of Medical Media on November 16, 2005. From April 2004 to November 16,
2005, Mr. Richardson served as Chairman of the Board, President, Chief Executive
Officer, and Treasurer of AFMN, Inc. and African American Medical Network,  Inc.
Mr.  Richardson  continues  to serve as a director of African  American  Medical
Network,  Inc. From March 2001 to April 2004, Mr.  Richardson served as Director
of Healthcare Marketing with Footsteps,  LLC, a marketing and advertising agency
specializing in culturally  relevant,  customized  communications  targeting the
multicultural  marketplace.  Footsteps, LLC is the multicultural  communications
company affiliated with Omnicom,  one of the world's largest  advertising agency
holding  companies.  From March  1996 to  February  2001,  he was  President  of
TRIAD/TRG, Inc., a marketing and advertising communications company specializing
in the African  American market providing  market  research,  public  relations,
sales  promotion,   and  strategic  planning  to  Fortune  1000  companies,  the
healthcare   industry,   and  government   agencies.   He  is  a  marketing  and
communications  expert who has specialized in the urban consumer market for more
than 25 years. His special expertise in the African American consumer market has
led to many  accomplishments,  including:  (i)  creating  award  winning,  image
enhancing,  communications  and community  outreach  campaigns that successfully
generated  bottom-line  results;  (ii)  implementing  successful  communications
programs for  healthcare  clients to educate and inform target  audiences  about
best practices,  preventative care, and treatments for asthma,  AIDS, stress and
high  blood  pressure,  and  diabetes;  and (iii)  corporate  involvements  with
assignments in managerial  market research  positions at Squibb,  Beechnut,  and
Lever Brothers.  In 1972, Mr.  Richardson  founded the first marketing  research
company  in the United  States to focus  exclusively  on the Black and  Hispanic
consumer  markets.  Mr.  Richardson has been a regular  lecturer on relationship
marketing  and  has  taught  seminars  on  marketing  and  promoting  healthcare
awareness and  preventative  care to urban consumers for the New York Department
of Social  Services.  He earned a B.A.  in Business  Administration  at Syracuse
University and has served on the University's  Public Relations Advisory Council
for more than 8 years.

      Randall Maxey,  M.D. -- Dr. Maxey was elected to the board of directors of
Medical Media on November 16, 2005. Previously,  Dr. Maxey served as director of
AFMN, Inc. He currently  serves as director of African American Medical Network,
Inc. and is the  Chairman of its Medical  Advisory  Board.  In the course of his
scientific and academic career, Dr. Maxey has made outstanding  contributions to
research  regarding the prevention and treatment of renal failure  especially in
cases complicated by cardiovascular  disease.  Over the years, his work has been
recognized  with  awards  from  peers,  colleagues,   and  medical  professional
organizations,  i.e.  the  National  Medical  Association  and the Golden  State
Medical Association.  In 1998, one of Dr. Maxey's most significant  achievements
was  recognized by Guam Memorial  Hospital  where he provided new  approaches to
preventing renal failure to diabetes  mellitus and hypertension in South Pacific
Islanders.

      Dr. Maxey earned his bachelor's  degree in pharmacy from the University of
Cincinnati in 1966, and concurrently,  his Ph.D. in cardiovascular  pharmacology
from Howard University  Graduate School and M.D. from Howard University  College
of Medicine (1966-1972).  Following  post-graduate training in the department of
medicine at Harlem Hospital Center,  Dr. Maxey was a postdoctoral  fellow at the
State University of New York at Downstate Medical Center in Brooklyn,  New York.
From 1973 to 1996,  Dr. Maxey served as director of nephrology at Daniel Freeman
Hospital  and Robert F. Kennedy  Medical  Center,  both  located in  California.
Currently,  Dr. Maxey is serving concurrent  positions as medical director,  and
supervising  medical director in California,  and at various  locations in Guam.
Similarly,   Dr.  Maxey  also  has  concurrent  hospital  appointments  in  both
California and Guam.

                                       5
A devoted educator and mentor, Dr. Maxey has held academic appointments at
Charles R. Drew University,  California, Downstate Medical Center, New York, and
Howard   University,   Washington,   D.C.,   where  he  directed   the  Academic
Reinforcement Program and taught the basic sciences in the College of Dentistry.

      Donald R.  Mastropietro -- Mr.  Mastropietro  was elected as a director of
Medical Media on December 2, 2005 and he currently  serves as Sr. Vice President
Finance,  Chief  Financial  Officer,  Treasurer,  and Assistant  Secretary.  Mr.
Mastropietro  started with Medical Media in August 2002. From May 1999 to August
2002, Mr.  Mastropietro  held accounting  positions with  Intelliworxx,  Inc., a
publicly  traded company  specializing in the design,  manufacture,  and sale of
hand-held  computers,  also serving as Corporate Secretary from March 2000. From
1996  until he joined  Intelliworxx,  Mr.  Mastropietro  worked  as a  financial
consultant  for several  public and  private  companies.  From 1993 to 1996,  he
served as Chief Financial Officer of EVRO Corporation, a publicly traded holding
company.  From 1972 to 1993, Mr. Mastropietro held several accounting  positions
at  Teltronics,  Inc, a publicly  traded  company  specializing  in the  design,
manufacture,  and sale of  telecommunication  equipment,  serving  the last five
years as Vice President of Finance,  Chief  Financial  Officer,  Secretary,  and
Treasurer.

      Michael  Marcovsky -- Mr.  Marcovsky  was elected as a director of Medical
Media on December 1, 2005. He  previously  served as a director of Medical Media
from April 19, 2004 through  November 16,  2005.  From 1980 to the present,  Mr.
Marcovsky  has  served as  President  and owner of Marnel  Associates,  Ltd.,  a
multi-tiered,   Los  Angeles-based   communications  firm  where  Mr.  Marcovsky
developed  strategies  for entry  into new arenas of pay  television,  cable and
pay-per-view for a list of clients that includes Citibank,  CBS, ABC, Cox Cable,
and Playboy Enterprises. From 1990 to 1994, Mr. Marcovsky served as Chairman and
CEO of The  Nostalgia  Network,  Inc. He is a pioneer in the cable and  cellular
communications  industries  and has intensive  experience  in the  entertainment
arena regarding Pay TV, Internet/E Commerce,  and Pay-Per-View.  Previously,  he
was Vice President of Program  Operations  with Warner Cable,  Vice President of
Pay-TV for Buena Vista  Distribution  (a  division of Walt Disney  Productions),
President of Golden West  Subscription  Television  and member of the  Executive
Committee of Golden West  Broadcasters.  As adjunct  professor at St. John's and
New York  Universities,  Mr. Marcovsky holds a Bachelor of Science from New York
University, and an MBA from Fordham University.

Appointment of Principal Officers

      On  December  2, 2005,  the  Company  appointed  its  principal  Executive
         Officers as:

      Philip M. Cohen, Chairman, President, Chief Executive Officer

      Donald R.  Mastropietro,  Sr.  Vice  President  Finance,  Chief  Financial
         Officer, Treasurer, and Assistant Secretary

      Charles V.  Richardson,  Sr. Vice  President  Marketing,  Chief  Marketing
         Officer

      Teresa  J.  Bray,  Vice  President  Administration/Compliance,   Corporate
         Secretary

      A biographical sketch of the new executive officer, Charles V. Richardson,
        is included above.

      On December 2, 2005, the Company ratified a five-year Employment Agreement
with Donald R.  Mastropietro  with an effective  date of November 16, 2005.  The
material terms of the Employment Agreement are as follows: (a) base compensation
of $128,400  per year,  plus  medical  insurance;  (b) salary  increases  at the
discretion  of the board of  directors  of the Company;  (c)  terminable  by the
Company at any time, for cause,  with notice and sixty days to cure any material
breach of the employment agreement; (d) terminable by the Company without cause,
with notice and payment of six months'  severance pay

                                       6
based on compensation then in effect;  (e) terminable by Mr.  Mastropietro,  for
cause,  with notice and the Company's payment of six months' severance pay based
on compensation then in effect; and (f) terminable by Mr. Mastropietro,  without
cause,  with  notice.  On  December  2, 2005,  the  Company  ratified  the First
Amendment to the  Employment  Agreement  (the  "Amendment  Agreement")  with Mr.
Mastropietro  with an effective date of November 29, 2005. The principal term of
the Amendment  Agreement was that Mr.  Mastropietro's  current salary of $90,000
will remain in effect until such time as the increased salary of $128,400 as set
forth in the Employment  Agreement can be paid through cash flow from operations
of the Company.

      On December 2, 2005, the Company ratified a five-year Employment Agreement
with Teresa J. Bray with an effective  date of November  16, 2005.  The material
terms of the  Employment  Agreement  are as follows:  (a) base  compensation  of
$118,400  per  year,  plus  medical  insurance;  (b)  salary  increases  at  the
discretion  of the board of  directors  of the Company;  (c)  terminable  by the
Company at any time, for cause,  with notice and sixty days to cure any material
breach of the employment agreement; (d) terminable by the Company without cause,
with notice and payment of six months'  severance pay based on compensation then
in effect;  (e) terminable by Ms. Bray, for cause, with notice and the Company's
payment of six months' severance pay based on compensation  then in effect;  and
(f) terminable by Ms. Bray, without cause, with notice. On December 2, 2005, the
Company ratified the First Amendment to the Employment Agreement (the "Amendment
Agreement")  with Ms. Bray with an  effective  date of November  29,  2005.  The
principal term of the Amendment  Agreement was that Ms. Bray's current salary of
$80,000  will  remain  in effect  until  such  time as the  increased  salary of
$118,400 as set forth in the Employment  Agreement can be paid through cash flow
from operations of the Company.

      On December 2, 2005,  the Company  ratified an Employment  Agreement  with
Charles V.  Richardson with an effective date of November 16, 2005. The material
terms of the  Employment  Agreement  are as follows:  (a) base  compensation  of
$150,000  per  year,  plus  medical  insurance;  (b)  salary  increases  at  the
discretion  of the board of  directors  of the Company;  (c)  terminable  by the
Company at any time, for cause,  with notice and sixty days to cure any material
breach of the employment agreement; (d) terminable by the Company without cause,
with notice and payment of six months'  severance pay based on compensation then
in effect;  (e)  terminable by Mr.  Richardson,  for cause,  with notice and the
Company's  payment of six months'  severance pay based on  compensation  then in
effect;  and (f) terminable by Mr.  Richardson,  without cause, with notice. The
Employment Agreement has a termination date of March 31, 2009.

Section 9 - Financial Statements and Exhibits

Item 9.01. Financial Statements and Exhibits

      (a)   Financial Statements

            None.

      (b)   Pro Forma Financial Information

            None.

      (c)   Exhibits

            10.1  Form of Note Purchase Agreement

            10.2  Form of Convertible Promissory Note

                                       7
10.3  Form of Common Stock Purchase Warrant

            10.4  Employment   Agreement  between  the  Company  and  Donald  R.
                  Mastropietro dated November 16, 2005

            10.5  First  Amendment  to the  Employment  Agreement  of  Donald R.
                  Mastropietro dated November 29, 2005

            10.6  Employment  Agreement  between  the Company and Teresa J. Bray
                  dated November 16, 2005

            10.7  First Amendment to the Employment  Agreement of Teresa J. Bray
                  dated November 29, 2005

            10.8  Employment  Agreement  between  the  Company  and  Charles  V.
                  Richardson dated November 16, 2005

                                   SIGNATURES

      Pursuant to the  requirements of the Securities  Exchange Act of 1934, the
Registrant  has duly  caused  this  report  to be  signed  on its  behalf by the
undersigned thereunto duly authorized.

                                         MEDICAL MEDIA TELEVISION, INC.
                                                (Registrant)

Date:    December 6, 2005                By: /s/Philip M. Cohen
                                             ------------------------------
                                             Philip M. Cohen, President and
                                             Chief Executive Officer

                                       8